Weekly Paclitaxel ANC Limit
For weekly paclitaxel therapy, do not administer if the absolute neutrophil count (ANC) is below 1,500 cells/mm³. This threshold applies to both initiating treatment and continuing subsequent cycles.
FDA-Approved ANC Requirements
The paclitaxel FDA label is explicit about hematologic monitoring requirements 1:
- Baseline requirement: Paclitaxel therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm³
- Retreatment threshold: Patients should not be retreated with subsequent cycles until neutrophils recover to a level >1,500 cells/mm³ AND platelets recover to >100,000 cells/mm³
- Monitoring frequency: Frequent peripheral blood cell counts should be performed on all patients receiving paclitaxel to monitor for myelotoxicity
Dose Modifications for Severe Neutropenia
If severe neutropenia develops during treatment (ANC <500 cells/mm³ for seven days or more), a 20% dose reduction is recommended for all subsequent courses 1.
The FDA label emphasizes that the incidence of neurotoxicity and severity of neutropenia both increase with dose, making adherence to these thresholds critical for patient safety 1.
Special Population: AIDS-Related Kaposi's Sarcoma
The only exception to the 1,500 cells/mm³ rule is for patients with AIDS-related Kaposi's sarcoma, where paclitaxel can be initiated and repeated if the neutrophil count is at least 1,000 cells/mm³ 1. This lower threshold reflects the baseline immunosuppression in this population and includes additional safety measures:
- Reduced dexamethasone premedication (10 mg instead of 20 mg)
- 20% dose reduction for severe neutropenia episodes
- Concomitant G-CSF as clinically indicated
Growth Factor Support
Growth factors (G-CSF) can be used in combination with paclitaxel for patients with resistant neutropenia 2. However, the primary threshold of ANC ≥1,500 cells/mm³ remains the standard for treatment administration in solid tumors.
Common pitfall: Do not confuse the weekly paclitaxel ANC threshold (1,500 cells/mm³) with the lower thresholds used for tyrosine kinase inhibitors in CML management, which range from 500-1,000 cells/mm³ depending on the specific agent 3, 4. These are entirely different drug classes with different toxicity profiles.